266 related articles for article (PubMed ID: 32525093)
1. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
Delaleu J; Deniau B; Battistella M; de Masson A; Bensaid B; Jachiet M; Lazaridou I; Bagot M; Bouaziz JD;
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2777-2779.e1. PubMed ID: 32525093
[No Abstract] [Full Text] [Related]
2. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.
Litaiem N; Hajlaoui K; Karray M; Slouma M; Zeglaoui F
Dermatol Ther; 2020 Jul; 33(4):e13565. PubMed ID: 32401410
[No Abstract] [Full Text] [Related]
3. Facts, not Fear: Safety of Hydroxychloroquine.
Kuraitis D; Murina A
Am J Med Sci; 2020 Aug; 360(2):199-200. PubMed ID: 32560964
[No Abstract] [Full Text] [Related]
4. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.
Schwartz RA; Janniger CK
Dermatol Ther; 2020 May; 33(3):e13380. PubMed ID: 32253799
[TBL] [Abstract][Full Text] [Related]
5. How to manage rheumatic patients during the coronavirus pandemic.
Parisi S; Ditto MC; Finucci A; Fusaro E
Panminerva Med; 2020 Sep; 62(3):176-177. PubMed ID: 32343511
[No Abstract] [Full Text] [Related]
6. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation.
Duman H; Topal IO; Kocaturk E; Cure K; Mansuroglu I
An Bras Dermatol; 2017; 92(3):404-406. PubMed ID: 29186260
[TBL] [Abstract][Full Text] [Related]
7. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19).
Robustelli Test E; Vezzoli P; Carugno A; Raponi F; Gianatti A; Rongioletti F; Sena P
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e457-e459. PubMed ID: 32386448
[No Abstract] [Full Text] [Related]
8. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.
Pereira BB
J Toxicol Environ Health B Crit Rev; 2020 May; 23(4):177-181. PubMed ID: 32281481
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions.
Shih RD; Johnson HM; Maki DG; Hennekens CH
Am J Med; 2020 Sep; 133(9):1007-1008. PubMed ID: 32502485
[No Abstract] [Full Text] [Related]
10. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.
Monte Serrano J; Cruañes Monferrer J; García-García M; García-Gil MF
Med Clin (Barc); 2020 Sep; 155(5):231. PubMed ID: 32522372
[No Abstract] [Full Text] [Related]
11. Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.
Sun X; Ni Y; Zhang M
Emerg Microbes Infect; 2020 Dec; 9(1):830-832. PubMed ID: 32338155
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence.
Cairoli E; Espinosa G
Med Clin (Barc); 2020 Aug; 155(3):134-135. PubMed ID: 32425245
[No Abstract] [Full Text] [Related]
13. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Coleman I; Ruiz G; Brahmbhatt S; Ackerman L
J Med Case Rep; 2020 Nov; 14(1):210. PubMed ID: 33138853
[TBL] [Abstract][Full Text] [Related]
14. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
[No Abstract] [Full Text] [Related]
15. Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing.
Harrigan JJ; Hubbard RA; Thomas S; Riello RJ; Bange E; Mamtani M; Mamtani R
J Gen Intern Med; 2020 Sep; 35(9):2826-2828. PubMed ID: 32542496
[No Abstract] [Full Text] [Related]
16. Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic.
Scuccimarri R; Sutton E; Fitzcharles MA
J Rheumatol; 2020 Jun; 47(6):783-786. PubMed ID: 32241801
[No Abstract] [Full Text] [Related]
17. Chloroquine and hydroxychloroquine in covid-19.
Ferner RE; Aronson JK
BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
[No Abstract] [Full Text] [Related]
18. [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Malek SA; Bouchti IE
Pan Afr Med J; 2020; 35(Suppl 2):134. PubMed ID: 33193949
[TBL] [Abstract][Full Text] [Related]
19. COVID-19: an unexpected indication for anti-rheumatic therapies?
Lucchino B; Di Franco M; Conti F
Rheumatology (Oxford); 2020 Jun; 59(6):1200-1203. PubMed ID: 32374874
[No Abstract] [Full Text] [Related]
20. Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine.
Haraszti S; Sendil S; Jensen N
Am J Case Rep; 2020 Oct; 21():e926901. PubMed ID: 33097683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
